Track Etoricoxib Price Report Historical and Forecast

Etoricoxib Price Trend and Forecast: Q4 2024 - Q3 2025

Executive Summary

The global Etoricoxib market has exhibited a dynamic price trajectory over the past year, influenced by a complex interplay of supply, demand, trade flows, and macroeconomic factors. For the quarter ending September 2025, Etoricoxib prices experienced notable declines across North America, Asia-Pacific (APAC), and Europe. Key drivers included oversupply from Asian exporters, elevated inventory levels, weak pharmaceutical procurement, freight rate fluctuations, and tariff uncertainties.

Despite recent softening, the market is poised for gradual stabilization as restocking activities resume, downstream demand slowly strengthens, and production cost pressures moderate. Historical quarterly performance from Q4 2024 through Q3 2025 reveals the market's sensitivity to geopolitical factors, export competitiveness, and raw material trends. With supply chains navigating volatility, buyers are advised to closely monitor procurement timing, inventory management, and trade flows to optimize purchasing strategies.

◼ Get Instant Access to Live Etoricoxib Prices Today: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Etoricoxib

Introduction

Etoricoxib, a nonsteroidal anti-inflammatory drug (NSAID) widely used in pharmaceutical formulations, is traded globally in USP-grade form. Pricing dynamics are influenced by regional demand from pharmaceutical manufacturers, export competitiveness of key producers in Asia, inventory cycles, logistics constraints, and currency fluctuations.

The period from Q4 2024 to Q3 2025 reflects pronounced market fluctuations, where early 2025 saw moderate price increases driven by supply constraints and tariffs, followed by significant declines in mid-2025 due to oversupply and weakened demand. This report provides an in-depth examination of the global Etoricoxib market, highlighting quarterly movements, regional analysis, production and cost trends, and procurement outlooks, enabling stakeholders to navigate market volatility with informed strategies.

Global Price Overview

Across major markets, Etoricoxib has experienced varying price pressures:

North America: The Etoricoxib Price Index fell 15.27% in Q3 2025 compared to the previous quarter, with average prices at USD 68,105/MT (CFR Houston). Oversupply, weak downstream demand, and tariff uncertainty were primary contributors.

APAC (China): A similar quarter-over-quarter decline of 15.28% brought average prices to USD 68,000/MT. High inventories and limited export demand weighed on pricing, although domestic replenishment offered modest support.

Europe (Germany): Prices dropped 15.26% quarter-over-quarter to USD 68,090/MT. Competitive Asian export offers, weak pharmaceutical demand, and inventory overhang contributed to subdued price levels.

Global pricing dynamics reflect the interlinked nature of international supply chains, with freight volatility, tariff policies, and currency movements directly influencing landed costs and procurement behavior.

◼ Monitor Real-Time Etoricoxib Price Swings and Stay Ahead of Competitors: https://www.chemanalyst.com/Pricing-data/etoricoxib-1634

Regional Analysis

North America

Q3 2025 Overview

The U.S. Etoricoxib market faced significant downward pressure in September 2025. Spot prices softened amid excess imports from Asia, elevated domestic inventories, and weak pharmaceutical demand. Freight rate fluctuations and tariff uncertainty added complexity to procurement decisions, impacting landed costs and buyer strategies.

Average Price: USD 68,105/MT (CFR Houston)

Price Index Movement: -15.27% quarter-over-quarter

Demand Outlook: Subdued due to cautious downstream manufacturing activity

Production Cost Trend: Moderately downward, offset by freight variations

Reasons for Price Changes

Oversupply: Reduced Asian export prices increased imports, saturating the market.

Weakened Demand: Pharmaceutical formulators deferred procurement, limiting upward price movement.

Logistics and Tariff Effects: Freight rate volatility and tariff uncertainties altered landed costs, influencing market offers.

Historical Quarterly Review

June 2025: Sharp decline due to aggressive Asian export offers and high inventory.

July 2025: Continued oversupply and muted restocking caused further price reductions.

Q1 2025: Moderate price increases occurred due to stable pharmaceutical demand, supply constraints, rising raw material costs, and tariffs on Chinese imports.

Q4 2024: Market remained largely stable, with modest softening in December amid year-end inventory adjustments.

Asia-Pacific (APAC)

Q3 2025 Overview

China's Etoricoxib market mirrored global softness, with spot prices and indices falling amid high inventory levels and weak export demand. Domestic pharmaceutical offtake provided partial support, while freight rates and currency fluctuations limited international competitiveness.

Average Price: USD 68,000/MT (FOB Shanghai)

Price Index Movement: -15.28% quarter-over-quarter

Demand Outlook: Slight improvement in domestic demand, but weak international purchase momentum

Production Cost Trend: Input cost declines tempered by rising raw material inflation and higher freight charges

Reasons for Price Changes

Inventory Pressure: Elevated stock levels prompted suppliers to offer discounts.

Export Challenges: Weak overseas orders, coupled with high freight costs, reduced demand support.

Cost Factors: Earlier reductions in input costs were partially offset by resurgent raw material inflation.

Historical Quarterly Review

July 2025: Fourth consecutive monthly decline in export prices due to oversupply and muted demand in US and EU markets.

Q1 2025: Moderate price increases driven by stable domestic demand, regulatory compliance costs, and rising raw material prices.

Q4 2024: Prices remained stable throughout, supported by consistent domestic consumption and disciplined production management.

Europe

Q3 2025 Overview

Germany, representing a significant European market, saw Etoricoxib prices soften sharply in September 2025. Domestic inventories, combined with discounted Asian exports, limited buyers' willingness to purchase at higher levels.

◼ Track Daily Etoricoxib Price Updates and Strengthen Your Procurement Decisions: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Etoricoxib

Average Price: USD 68,090/MT (CFR Hamburg)

Price Index Movement: -15.26% quarter-over-quarter

Demand Outlook: Weak, as pharmaceutical buyers deferred orders amid high inventories

Production Cost Trend: Slight easing due to lower raw material prices and competitive Asian offers

Reasons for Price Changes

Inventory Overhang: High stock levels in local markets limited price recovery.

Asian Export Discounts: Aggressive pricing from China reduced landed costs and pressured European offers.

Demand Weakness: Pharmaceutical sector and healthcare demand remained subdued, discouraging procurement.

Historical Quarterly Review

June-July 2025: Prices declined due to oversupply and cautious restocking.

Q1 2025: Moderate increases driven by supply-side constraints and steady demand.

Q4 2024: Market remained stable before slight softening in December, consistent with seasonal inventory adjustments.

Production and Cost Structure Insights

Etoricoxib pricing is highly sensitive to raw material costs, production capacity utilization, and freight logistics:

Raw Material Costs: Fluctuations in pharmaceutical intermediates and energy prices influence production expenses. Early 2025 saw rising raw material costs supporting price increases, while mid-2025 experienced partial relief offset by renewed input inflation.

Production Output: Scheduled plant maintenance and resumption cycles affect supply availability and pricing dynamics.

Freight and Tariffs: International shipments are sensitive to shipping cost volatility and import tariffs, which can alter landed prices and market competitiveness.

Procurement Behavior and Supply Conditions

Buyers have demonstrated cautious procurement behavior throughout 2025, responding to:

High Inventories: Both in domestic warehouses and export hubs, reducing urgency for immediate purchase.

Oversupply Pressure: Aggressive Asian export pricing incentivized buyers to wait for favorable pricing windows.

Downstream Demand: Pharmaceutical formulators limited purchases due to slow consumption trends, prolonging destocking cycles.

Supply conditions remain well-balanced globally, with major producers operating near-normal output levels while exporters manage stock clearance through competitive offers.

Logistics and Trade-Flow Impacts

Freight Volatility: Rising shipping costs during mid-2025 influenced landed costs in all regions, affecting procurement timing.

Currency Movements: Fluctuations in USD, Euro, and CNY impacted import competitiveness and profit margins for international buyers.

Export Discounts: Chinese suppliers' aggressive pricing undercut local markets in North America and Europe, compressing margins for domestic suppliers.

Price Forecast

Based on current market conditions:

North America: Prices are expected to see a modest recovery as restocking resumes, though sustained oversupply may limit upside potential.

APAC: Stable-to-soft pricing anticipated, with downward bias likely to persist unless major restocking occurs in Western markets.

Europe: Mild recovery is possible in the coming months, driven by selective restocking and downstream pharmaceutical demand.

◼ Unlock Live Pricing Dashboards for Accurate and Timely Insights: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Etoricoxib

FAQ Section

Q1: Why did Etoricoxib prices decline sharply in Q3 2025?
A1: Prices declined due to oversupply from discounted Asian exports, high inventory levels, weak pharmaceutical demand, and freight and tariff uncertainties.

Q2: What drove price increases in Q1 2025?
A2: Early 2025 increases were driven by supply constraints, rising raw material costs, 10% tariffs on Chinese imports, and consistent pharmaceutical sector demand.

Q3: How does freight affect Etoricoxib pricing?
A3: Freight volatility influences landed costs. Higher shipping charges increase procurement expenses, reducing buyer activity, while lower rates can improve import competitiveness.

Q4: What role do inventories play in pricing?
A4: Elevated inventories reduce buying urgency, leading suppliers to offer discounts to clear stock, while low inventories can support upward price momentum.

Q5: How can buyers optimize procurement in volatile markets?
A5: Buyers should monitor real-time price trends, forecast data, inventory levels, and trade flows to time purchases effectively and mitigate risk from oversupply or logistics fluctuations.

How ChemAnalyst Supports Buyers

ChemAnalyst provides actionable intelligence to navigate the Etoricoxib market effectively:

Real-Time Market News: Updates on global prices, demand-supply dynamics, and trade flows for over 450 commodities.

Price Forecasts: Forward-looking insights to optimize procurement strategies and reduce cost exposure.

Supply-Chain Intelligence: Monitoring plant shutdowns, logistics disruptions, and regional market movements to anticipate potential supply risks.

Expert Analysis: Chemical engineers and market analysts offer in-depth explanations behind price trends, enabling informed decision-making.

Global Coverage: Field teams operate across major trading ports, ensuring timely, first-hand market intelligence for North America, APAC, and Europe.

ChemAnalyst empowers procurement teams to manage volatility, improve supply-chain resilience, and capitalize on favorable market conditions through comprehensive data-driven insights.

◼ Stay Updated Each Day with Verified Etoricoxib Price Movements: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Etoricoxib

Conclusion

The Etoricoxib market has demonstrated considerable volatility over the past year, with supply-demand imbalances, inventory pressures, and international trade dynamics driving sharp quarterly price movements. While mid-2025 saw notable declines across all major regions, moderate recovery is expected as restocking resumes and pharmaceutical demand stabilizes.

Contact Us:

UNITED STATES

Call +1 3322586602

420 Lexington Avenue, Suite 300, New York, NY,

United States, 10170

Germany

Call +49-221-6505-8833

S-01, 2.floor, Subbelrather Straße,

15a Cologne, 50823, Germany

Website: https://www.chemanalyst.com/

About Us:

Welcome to ChemAnalyst, a next-generation platform for chemical and petrochemical intelligence where innovation meets practical insight. Recognized as "Product Innovator of the Year 2023" and ranked among the "Top 100 Digital Procurement Solutions Companies," we lead the digital transformation of the global chemical sector. Our online platform helps companies handle price volatility with structured analysis, real-time pricing, and reliable news and deal updates from across the world. Tracking over 500 chemical prices in more than 40 countries becomes simple and efficient with us.

This release was published on openPR.